Do selective serotonin reuptake inhibitors enhance post-stroke recovery beyond mood? An updated, narrative mini-review

Giulio Verrienti

Exploration of Neuroprotective Therapy ›› 2026, Vol. 6 ›› Issue (1) : 1004165

PDF (1660KB)
Exploration of Neuroprotective Therapy ›› 2026, Vol. 6 ›› Issue (1) :1004165 DOI: 10.37349/ent.2026.1004165
Mini Review
research-article
Do selective serotonin reuptake inhibitors enhance post-stroke recovery beyond mood? An updated, narrative mini-review
Author information +
History +
PDF (1660KB)

Abstract

Stroke remains a leading cause of long-term disability worldwide, and selective serotonin reuptake inhibitors (SSRIs), beyond their established role in treating post-stroke depression, have been investigated for potential neurorestorative effects through modulation of neuroplasticity, cortical excitability, and synaptic remodeling. This narrative mini-review summarizes the current clinical evidence on the use of SSRIs for motor recovery, cognitive recovery, and global functional outcomes after stroke. Early small-scale studies, particularly with fluoxetine, suggested improvements in motor performance and neurophysiological markers of plasticity, generating interest in a possible disease-modifying role. However, subsequent large multicenter randomized controlled trials failed to demonstrate benefits on global functional outcomes and instead reported an increased risk of adverse events, including fractures, falls, seizures, and hyponatremia. Evidence for other SSRIs remains limited, heterogeneous, and largely inconclusive. The observed discrepancy between mechanistic plausibility and neutral clinical outcomes may reflect limitations in outcome sensitivity, patient heterogeneity, differences in stroke subtypes, and suboptimal alignment between biological targets and clinical endpoints. Overall, current data do not support the routine use of SSRIs as neurorestorative agents in non-depressed stroke patients. Future research should focus on biomarker-guided patient selection, optimized timing of intervention, and the use of domain-specific outcome measures more closely aligned with neuroplasticity mechanisms, in order to clarify whether serotonergic modulation may have a selective, context-dependent role in post-stroke recovery.

Keywords

stroke rehabilitation / selective serotonin reuptake inhibitors (SSRIs) / neuroplasticity / motor recovery / functional outcomes

Cite this article

Download citation ▾
Giulio Verrienti. Do selective serotonin reuptake inhibitors enhance post-stroke recovery beyond mood? An updated, narrative mini-review. Exploration of Neuroprotective Therapy, 2026, 6 (1) : 1004165 DOI:10.37349/ent.2026.1004165

登录浏览全文

4963

注册一个新账户 忘记密码

References

[1]

GBD 2019 Stroke Collaborators. Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Neurol. 2021; 20: 795-820.

[2]

Gittins M, Lugo-Palacios D, Vail A, Bowen A, Paley L, Bray B, et al. Stroke impairment categories: A new way to classify the effects of stroke based on stroke-related impairments. Clin Rehabil. 2021; 35: 446-58.

[3]

Chen CH, Chang TY, Sung PS, Su HC, Chou CH, Tung H, et al. An overview of post-stroke disability. J Formos Med Assoc. 2026; 125 Suppl 1: S32-47.

[4]

Chollet F, Rigal J, Marque P, Barbieux-Guillot M, Raposo N, Fabry V, et al. Serotonin Selective Reuptake Inhibitors (SSRIs) and Stroke. Curr Neurol Neurosci Rep. 2018; 18: 100.

[5]

Gu SC, Wang CD. Early Selective Serotonin Reuptake Inhibitors for Recovery after Stroke: A Meta-Analysis and Trial Sequential Analysis. J Stroke Cerebrovasc Dis. 2018; 27: 1178-89.

[6]

Rosas-Sánchez GU, Germán-Ponciano LJ, Guillen-Ruiz G, Cueto-Escobedo J, Limón-Vázquez AK, Rodríguez-Landa JF, et al. Neuroplasticity and Mechanisms of Action of Acute and Chronic Treatment with Antidepressants in Preclinical Studies. Biomedicines. 2024; 12: 2744.

[7]

Schneider CL, Majewska AK, Busza A, Williams ZR, Mahon BZ, Sahin B. Selective serotonin reuptake inhibitors for functional recovery after stroke: similarities with the critical period and the role of experience-dependent plasticity. J Neurol. 2021; 268: 1203-9.

[8]

Batsikadze G, Paulus W, Kuo MF, Nitsche MA. Effect of serotonin on paired associative stimulation-induced plasticity in the human motor cortex. Neuropsychopharmacology. 2013; 38: 2260-7.

[9]

Guggisberg AG, Koch PJ, Hummel FC, Buetefisch CM. Brain networks and their relevance for stroke rehabilitation. Clin Neurophysiol. 2019; 130: 1098-24.

[10]

Pinto CB, Saleh Velez FG, Lopes F, de Toledo Piza PV, Dipietro L, Wang QM, et al. SSRI and Motor Recovery in Stroke: Reestablishment of Inhibitory Neural Network Tonus. Front Neurosci. 2017; 11: 637.

[11]

Santarelli L, Saxe M, Gross C, Surget A, Battaglia F, Dulawa S, et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science. 2003; 301: 805-9.

[12]

Castrén E, Rantamäki T. The role of BDNF and its receptors in depression and antidepressant drug action: Reactivation of developmental plasticity. Dev Neurobiol. 2010; 70: 289-97.

[13]

Li Y, Luikart BW, Birnbaum S, Chen J, Kwon CH, Kernie SG, et al. TrkB regulates hippocampal neurogenesis and governs sensitivity to antidepressive treatment. Neuron. 2008; 59: 399-412.

[14]

Reed MB, Vanicek T, Seiger R, Klöbl M, Spurny B, Handschuh P, et al. Neuroplastic effects of a selective serotonin reuptake inhibitor in relearning and retrieval. Neuroimage. 2021; 236: 118039.

[15]

Melo L, Beaupain MC, Ghanavati E, Kuo MF, Nitsche MA. Neurochemical mechanisms underlying serotonergic modulation of neuroplasticity in humans. Brain Stimul. 2024; 17: 421-30.

[16]

Lambertsen KL, Biber K, Finsen B. Inflammatory cytokines in experimental and human stroke. J Cereb Blood Flow Metab. 2012; 32: 1677-98.

[17]

Iadecola C. The pathobiology of vascular dementia. Neuron. 2013; 80: 844-66.

[18]

Finnema SJ, Halldin C, Bang-Andersen B, Bundgaard C, Farde L. Serotonin transporter occupancy by escitalopram and citalopram in the non-human primate brain: a [(11)C]MADAM PET study. Psychopharmacology (Berl). 2015; 232: 4159-67.

[19]

Acler M, Robol E, Fiaschi A, Manganotti P. A double blind placebo RCT to investigate the effects of serotonergic modulation on brain excitability and motor recovery in stroke patients. J Neurol. 2009; 256: 1152-8.

[20]

Thorstensen JR, Henderson TT, Kavanagh JJ. Serotonergic and noradrenergic contributions to motor cortical and spinal motoneuronal excitability in humans. Neuropharmacology. 2024; 242: 109761.

[21]

Conti S, Spalletti C, Pasquini M, Giordano N, Barsotti N, Mainardi M, et al. Combining robotics with enhanced serotonin-driven cortical plasticity improves post-stroke motor recovery. Prog Neurobiol. 2021; 203: 102073.

[22]

Molloy EN, Zsido RG, Piecha FA, Beinhölzl N, Scharrer U, Zheleva G, et al. Decreased thalamo-cortico connectivity during an implicit sequence motor learning task and 7 days escitalopram intake. Sci Rep. 2021; 11: 15060.

[23]

Oh JS, Choo YJ, Chang MC. Effect of Selective Serotonin Reuptake Inhibitors on Motor Recovery After Stroke: A Systematic Meta-analysis. Am J Phys Med Rehabil. 2023; 102: 1097-101.

[24]

Chollet F, Tardy J, Albucher JF, Thalamas C, Berard E, Lamy C, et al. Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial. Lancet Neurol. 2011; 10: 123-30.

[25]

He Y, Cai Z, Zeng S, Chen S, Tang B, Liang Y, et al. Effect of fluoxetine on three-year recurrence in acute ischemic stroke: A randomized controlled clinical study. Clin Neurol Neurosurg. 2018; 168: 1-6.

[26]

He YT, Tang BS, Cai ZL, Zeng SL, Jiang X, Guo Y. Effects of Fluoxetine on Neural Functional Prognosis after Ischemic Stroke: A Randomized Controlled Study in China. J Stroke Cerebrovasc Dis. 2016; 25: 761-70.

[27]

Mikami K, Jorge RE, Adams HP Jr, Davis PH, Leira EC, Jang M, et al. Effect of antidepressants on the course of disability following stroke. Am J Geriatr Psychiatry. 2011; 19: 1007-15.

[28]

Jorge RE, Robinson RG, Arndt S, Starkstein S. Mortality and poststroke depression: a placebo-controlled trial of antidepressants. Am J Psychiatry. 2003; 160: 1823-9.

[29]

Pariente J, Loubinoux I, Carel C, Albucher JF, Leger A, Manelfe C, et al. Fluoxetine modulates motor performance and cerebral activation of patients recovering from stroke. Ann Neurol. 2001; 50: 718-29.

[30]

AFFINITY Trial Collaboration. Safety and efficacy of fluoxetine on functional outcome after acute stroke (AFFINITY): a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2020; 19: 651-60.

[31]

EFFECTS Trial Collaboration. Safety and efficacy of fluoxetine on functional recovery after acute stroke (EFFECTS): a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2020; 19: 661-9.

[32]

FOCUS Trial Collaboration. Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial. Lancet. 2019;393:265-74.

[33]

Kraglund KL, Mortensen JK, Damsbo AG, Modrau B, Simonsen SA, Iversen HK, et al. Neuroregeneration and Vascular Protection by Citalopram in Acute Ischemic Stroke (TALOS). Stroke. 2018; 49: 2568-76.

[34]

Savadi Oskouie D, Sharifipour E, Sadeghi Bazargani H, Hashemilar M, Nikanfar M, Ghazanfari Amlashi S, et al. Efficacy of Citalopram on Acute Ischemic Stroke Outcome: A Randomized Clinical Trial. Neurorehabil Neural Repair. 2017; 31: 638-47.

[35]

Zittel S, Weiller C, Liepert J. Citalopram improves dexterity in chronic stroke patients. Neurorehabil Neural Repair. 2008; 22: 311-4.

[36]

Jorge RE, Acion L, Moser D, Adams HP Jr, Robinson RG. Escitalopram and enhancement of cognitive recovery following stroke. Arch Gen Psychiatry. 2010; 67: 187-96.

[37]

Cao JX, Liu L, Sun YT, Zeng QH, Wang Y, Chen JC. Effects of the prophylactic use of escitalopram on the prognosis and the plasma copeptin level in patients with acute cerebral infarction. Braz J Med Biol Res. 2020; 53:e8930.

[38]

Kim JS, Lee EJ, Chang DI, Park JH, Ahn SH, Cha JK, et al. Efficacy of early administration of escitalopram on depressive and emotional symptoms and neurological dysfunction after stroke: a multicentre, double-blind, randomised, placebo-controlled study. Lancet Psychiatry. 2017; 4: 33-41.

[39]

Fugl-Meyer AR, Jääskö L, Leyman I, Olsson S, Steglind S. The post-stroke hemiplegic patient. 1. a method for evaluation of physical performance. Scand J Rehabil Med. 1975; 7: 13-31.

[40]

Banks JL, Marotta CA. Outcomes validity and reliability of the modified Rankin scale: implications for stroke clinical trials: a literature review and synthesis. Stroke. 2007; 38: 1091-6.

[41]

Kwah LK, Diong J. National Institutes of Health Stroke Scale (NIHSS). J Physiother. 2014; 60: 61.

[42]

Su D, Zhang Y, Wang A, Shao D, Xu F, Dong M, et al. Efficacy and tolerability of selective serotonin reuptake inhibitors on promoting motor recovery after stroke:meta-analysis of randomized controlled trials. Expert Rev Neurother. 2021; 21: 1179-89.

[43]

Su N, Wen C, Guo S, Yu Y, Wang C. The Efficacy and Tolerability of Selective Serotonin Reuptake Inhibitors for Motor Recovery in Non-depressed Patients After Acute Stroke: A Meta-Analysis. Front Neurol. 2021; 12: 749322.

[44]

Kamel MA, Abdelsattar NK, Taha TAA, Fadl ZA, Aboelmajd NO, Hejazi AMA, et al. Effect of antidepressants on motor and functional recovery in stroke: a systematic review and meta-analysis. BMC Neurol. 2026; 26: 58.

[45]

Mead G, Graham C, Lundström E, Hankey GJ, Hackett ML, Billot L, et al. Individual patient data meta-analysis of the effects of fluoxetine on functional outcomes after acute stroke. Int J Stroke. 2024; 19: 798-808.

[46]

Kalbouneh HM, Toubasi AA, Albustanji FH, Obaid YY, Al-Harasis LM. Safety and Efficacy of SSRIs in Improving Poststroke Recovery: A Systematic Review and Meta-Analysis. J Am Heart Assoc. 2022; 11: e025868.

[47]

Braun RG, Heitsch L, Cole JW, Lindgren AG, de Havenon A, Dude JA, et al. Domain-Specific Outcomes for Stroke Clinical Trials: What the Modified Rankin Isn't Ranking. Neurology. 2021; 97: 367-77.

[48]

Chaisinanunkul N, Starkman S, Gornbein J, Hamilton S, Chatfield F, Conwit R, et al. Staged use of ordinal and linear disability scales: a practical approach to granular assessment of acute stroke outcome. Front Neurol. 2023; 14: 1174686.

[49]

Niznick N, Saigle V, Marti ML, Laframboise J, Zha X, Andersen C, et al.; APOC Investigators and the Canadian Critical Care Trials Group. Patient Relevance of the Modified Rankin Scale in Subarachnoid Hemorrhage Research: An International Cross-sectional Survey. Neurology. 2023; 100: e1565-73.

[50]

Nobels-Janssen E, Postma EN, Abma IL, van Dijk JMC, de Ridder IR, Schenck H, et al. Validity of the modified Rankin Scale in patients with aneurysmal subarachnoid hemorrhage: a randomized study. BMC Neurol. 2024; 24: 23.

[51]

Erler KS, Wu R, DiCarlo JA, Petrilli MF, Gochyyev P, Hochberg LR, et al. Association of Modified Rankin Scale With Recovery Phenotypes in Patients With Upper Extremity Weakness After Stroke. Neurology. 2022; 98: e1877-85.

[52]

Verrienti G, Colonna I, Raccagni C. Use of vortioxetine in different neurological fields: a systematic review and future perspectives. Neurol Sci. 2025; 46: 2055-71.

[53]

Verrienti G, Lombardozzi G, Albergo G, De Filippis S. Trazodone in neurology, a new life for an old molecule-an updated, comprehensive, systematic review of clinical trials. Int J Psychiatry Clin Pract. 2026; 30: 12-22.

[54]

Rodoshi ZN, Shibu S, Omer O, Tallal H, Gondal MZD, Shahid Z, et al. Comparative Efficacy of Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) in the Management of Post-stroke Depression: A Systematic Review of Randomized Controlled Trials. Cureus. 2025; 17: e84784.

[55]

Lee EJ, Oh MS, Kim JS, Chang DI, Park JH, Cha JK, et al. Serotonin transporter gene polymorphisms may be associated with poststroke neurological recovery after escitalopram use. J Neurol Neurosurg Psychiatry. 2018; 89: 271-6.

[56]

Kohen R, Cain KC, Buzaitis A, Johnson V, Becker KJ, Teri L, et al. Response to psychosocial treatment in poststroke depression is associated with serotonin transporter polymorphisms. Stroke. 2011; 42: 2068-70.

[57]

Uher R, Huezo-Diaz P, Perroud N, Smith R, Rietschel M, Mors O, et al. Genetic predictors of response to antidepressants in the GENDEP project. Pharmacogenomics J. 2009; 9: 225-33.

[58]

Balkaya M, Cho S. Genetics of stroke recovery: BDNF val66met polymorphism in stroke recovery and its interaction with aging. Neurobiol Dis. 2019; 126: 36-46.

[59]

Stanne TM, Åberg ND, Nilsson S, Jood K, Blomstrand C, Andreasson U, et al. Low Circulating Acute Brain-Derived Neurotrophic Factor Levels Are Associated With Poor Long-Term Functional Outcome After Ischemic Stroke. Stroke. 2016; 47: 1943-5.

[60]

Liu J, Wang C. Microstructure and Genetic Polymorphisms: Role in Motor Rehabilitation After Subcortical Stroke. Front Aging Neurosci. 2022; 14: 813756.

[61]

Cassidy JM, Mark JI, Cramer SC. Functional connectivity drives stroke recovery: shifting the paradigm from correlation to causation. Brain. 2022; 145: 1211-28.

[62]

McDonnell MN, Stinear CM. TMS measures of motor cortex function after stroke: A meta-analysis. Brain Stimul. 2017; 10: 721-34.

[63]

Harquel S, Cadic-Melchior A, Morishita T, Fleury L, Witon A, Ceroni M, et al. Stroke Recovery-Related Changes in Cortical Reactivity Based on Modulation of Intracortical Inhibition. Stroke. 2024; 55: 1629-40.

[64]

Murphy TH, Corbett D. Plasticity during stroke recovery: from synapse to behaviour. Nat Rev Neurosci. 2009; 10: 861-72.

[65]

Cassidy JM, Cramer SC. Spontaneous and Therapeutic-Induced Mechanisms of Functional Recovery After Stroke. Transl Stroke Res. 2017; 8: 33-46.

PDF (1660KB)

0

Accesses

0

Citation

Detail

Sections
Recommended

/

〈 〉